No­var­tis nix­es PhII TGFß an­ti­body — and one-time 'wild card' — af­ter ben­e­fit-risk as­sess­ment

Eight years af­ter No­var­tis first li­censed an an­ti-TGFß an­ti­body from XO­MA, the Swiss phar­ma gi­ant is wind­ing down all de­vel­op­ment.

The drug, dubbed NIS793, was …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER